Jennifer Newman

Jennifer Newman is a Research Fellow specializing in neuro-oncology with a focus on central nervous system lymphoma treatment. Her primary affiliation appears connected to Memorial Sloan Kettering (indicated by Fulltext@MSK access) though formal institutional structure remains unspecified in available sources.

Her research centers on predictive biomarkers and therapeutic outcomes in primary CNS lymphoma (PCNSL), particularly examining CDKN2A alterations, HD-MTX chemotherapy response, and relapse patterns. Current work investigates predictors of induction therapy efficacy and progression mechanisms in PCNSL patients.

Analysis of her sole documented publication (2025) reveals concentrated expertise in translational neuro-oncology, with emphasis on clinical trial data interpretation and therapeutic optimization for rare CNS malignancies. The work demonstrates interdisciplinary collaboration across hematology, neurology, and oncology specialties.

No scientific awards or formal advising roles are documented in the provided materials. Her research appears integrated within clinical neuro-oncology teams focusing on lymphoma treatment protocols and biomarker validation.